Bank of Montreal Can Sells 21,120 Shares of Haemonetics Co. (NYSE:HAE)

Bank of Montreal Can lowered its stake in Haemonetics Co. (NYSE:HAE) by 18.0% during the first quarter, according to the company in its most recent filing with the SEC. The fund owned 95,968 shares of the medical instruments supplier’s stock after selling 21,120 shares during the period. Bank of Montreal Can owned approximately 0.19% of Haemonetics worth $10,919,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently made changes to their positions in the company. BNP Paribas Arbitrage SA grew its stake in Haemonetics by 570.5% in the 1st quarter. BNP Paribas Arbitrage SA now owns 59,739 shares of the medical instruments supplier’s stock valued at $6,632,000 after buying an additional 50,829 shares during the last quarter. Aperio Group LLC grew its stake in Haemonetics by 21.2% in the 4th quarter. Aperio Group LLC now owns 11,845 shares of the medical instruments supplier’s stock valued at $1,406,000 after buying an additional 2,069 shares during the last quarter. Pura Vida Investments LLC grew its stake in Haemonetics by 50.0% in the 4th quarter. Pura Vida Investments LLC now owns 82,500 shares of the medical instruments supplier’s stock valued at $9,797,000 after buying an additional 27,500 shares during the last quarter. Illinois Municipal Retirement Fund grew its stake in Haemonetics by 86.1% in the 4th quarter. Illinois Municipal Retirement Fund now owns 7,672 shares of the medical instruments supplier’s stock valued at $911,000 after buying an additional 3,549 shares during the last quarter. Finally, American International Group Inc. grew its stake in Haemonetics by 0.4% in the 1st quarter. American International Group Inc. now owns 92,586 shares of the medical instruments supplier’s stock valued at $10,278,000 after buying an additional 411 shares during the last quarter. Institutional investors and hedge funds own 97.34% of the company’s stock.

A number of research analysts recently commented on HAE shares. Citigroup started coverage on shares of Haemonetics in a research note on Thursday, June 17th. They issued a “buy” rating on the stock. CJS Securities upgraded shares of Haemonetics from a “market perform” rating to an “outperform” rating in a research report on Friday, May 14th. Morgan Stanley decreased their target price on shares of Haemonetics from $83.00 to $75.00 and set an “equal weight” rating on the stock in a research report on Friday, May 14th. Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell assumed coverage on shares of Haemonetics in a research report on Thursday, June 17th. They set a “buy” rating and a $75.00 target price on the stock. Finally, Jefferies Financial Group decreased their target price on shares of Haemonetics from $105.00 to $85.00 and set a “buy” rating on the stock in a research report on Friday, May 14th. Two analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $98.00.

In related news, Director Mark W. Kroll sold 11,813 shares of the stock in a transaction that occurred on Wednesday, May 26th. The shares were sold at an average price of $55.10, for a total value of $650,896.30. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Christopher Simon sold 1,024 shares of the firm’s stock in a transaction on Wednesday, May 19th. The shares were sold at an average price of $55.19, for a total transaction of $56,514.56. The disclosure for this sale can be found here. In the last three months, insiders sold 20,495 shares of company stock valued at $1,149,382. 1.44% of the stock is owned by insiders.

NYSE HAE opened at $65.01 on Friday. The company has a debt-to-equity ratio of 0.94, a current ratio of 2.74 and a quick ratio of 1.46. The firm has a market cap of $3.31 billion, a price-to-earnings ratio of 27.13, a price-to-earnings-growth ratio of 2.27 and a beta of 0.36. The stock’s 50 day moving average price is $61.84. Haemonetics Co. has a 1 year low of $49.26 and a 1 year high of $142.11.

Haemonetics (NYSE:HAE) last issued its quarterly earnings data on Thursday, May 13th. The medical instruments supplier reported $0.46 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.67 by ($0.21). The company had revenue of $225.00 million during the quarter, compared to the consensus estimate of $223.92 million. Haemonetics had a net margin of 9.13% and a return on equity of 17.70%. Haemonetics’s revenue for the quarter was down 5.7% on a year-over-year basis. During the same period in the previous year, the company earned $0.69 EPS. Equities research analysts predict that Haemonetics Co. will post 2.81 earnings per share for the current year.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system.

Further Reading: What is Elliott Wave theory?

Institutional Ownership by Quarter for Haemonetics (NYSE:HAE)

Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.